Health Care & Life Sciences » Biotechnology | Portola Pharmaceuticals Inc.

Portola Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
268,665.00
309,273.00
444,542.00
318,949.00
463,330.00
318,026
Total Accounts Receivable
703.00
97.00
1,019.00
44.00
3,776.00
15,729
Inventories
-
-
-
-
1,099.00
7,873
Other Current Assets
3,339.00
5,707.00
20,016.00
9,935.00
9,718.00
11,699
Total Current Assets
272,707.00
315,077.00
465,577.00
328,928.00
477,923.00
353,327
Net Property, Plant & Equipment
2,600.00
2,776.00
6,243.00
6,143.00
5,217.00
5,236
Total Investments and Advances
50,371.00
83,030.00
15,960.00
-
71,076.00
-
Intangible Assets
-
-
3,151.00
3,151.00
7,851.00
7,279
Other Assets
53.00
15,612.00
11,993.00
5,214.00
9,609.00
20,577
Total Assets
325,731.00
416,495.00
502,924.00
343,436.00
571,676.00
386,419
Accounts Payable
3,232.00
14,084.00
10,279.00
14,546.00
9,304.00
Other Current Liabilities
22,323.00
27,047.00
40,867.00
51,118.00
71,220.00
Total Current Liabilities
25,555.00
41,131.00
51,146.00
65,664.00
80,524.00
Long-Term Debt
-
-
-
57,815.00
112,816.00
Other Liabilities
3,841.00
27,562.00
21,455.00
27,268.00
28,843.00
Total Liabilities
29,396.00
68,693.00
72,601.00
150,747.00
222,183.00
Common Equity (Total)
296,335.00
347,802.00
427,396.00
190,532.00
346,866.00
Total Shareholders' Equity
296,335.00
347,802.00
427,396.00
190,532.00
346,866.00
Total Equity
296,335.00
347,802.00
430,323.00
192,689.00
349,493.00
Liabilities & Shareholders' Equity
325,731.00
416,495.00
502,924.00
343,436.00
571,676.00
Accumulated Minority Interest
-
-
2,927.00
2,157.00
2,627.00

About Portola Pharmaceuticals

View Profile
Address
270 East Grand Avenue
South San Francisco California 94080
United States
Employees -
Website http://www.portola.com
Updated 07/08/2019
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and hematologic disorders, and inflammation. Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation factor Xa (recombinant), inactivated-zhzo, the antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company was founded by Charles J.